FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220692731> ?p ?o ?g. }

• W4220692731 endingPage "H761" @default.
• W4220692731 startingPage "H749" @default.
• W4220692731 abstract "Alterations in cardiac metabolism are strongly associated with the pathogenesis of heart failure (HF). We recently reported that glutamine-dependent anaplerosis, termed glutaminolysis, was activated by H2O2 stimulation in rat cardiomyocytes, which seemed to be an adaptive response by which cardiomyocytes survive acute stress. However, the molecular mechanisms and fundamental roles of glutaminolysis in the pathophysiology of the failing heart are still unknown. Here, we treated wild-type mice (C57BL/6J) and rat neonatal cardiomyocytes (RNCMs) and fibroblasts (RNCFs) with angiotensin II (ANG II) to induce pathological cardiac remodeling. Glutaminase 1 (GLS1), a rate-limiting glutaminolysis enzyme, was significantly increased in ANG II-induced mouse hearts, RNCMs and RNCFs. Unexpectedly, a GLS1 inhibitor attenuated ANG II-induced left ventricular hypertrophy and fibrosis in the mice, and gene knockdown and pharmacological perturbation of GLS1 suppressed hypertrophy and the proliferation of RNCMs and RNCFs, respectively. Using mass spectrometry (MS)-based stable isotope tracing with 13C-labeled glutamine, we observed glutamine metabolic flux in ANG II-treated RNCMs and RNCFs. The incorporation of 13C atoms into tricarboxylic acid (TCA) cycle intermediates and their derivatives was markedly enhanced in both cell types, indicating the activation of glutaminolysis in hypertrophied hearts. Notably, GLS1 inhibition reduced the production of glutamine-derived aspartate and citrate, which are required for the biosynthesis of nucleic acids and lipids, possibly contributing to the suppression of cardiac hypertrophy and fibrosis. The findings of the present study reveal that GLS1-mediated upregulation of glutaminolysis leads to maladaptive cardiac remodeling. Inhibition of this anaplerotic pathway could be a novel therapeutic approach for HF.NEW & NOTEWORTHY To our knowledge, this study is the first to demonstrate that increased GLS1 expression and subsequent activation of glutaminolysis are associated with exacerbation of cardiac hypertrophy and fibrosis. Inhibiting GLS1 antagonized the adverse cardiac remodeling in vitro and in vivo, partly due to reduction of glutamine-derived metabolites, which are necessary for cellular growth and proliferation. Increased glutamine utilization for anabolic reactions in cardiac cells may be related to the pathogenesis and development of HF." @default.
• W4220692731 created "2022-04-03" @default.
• W4220692731 creator A5000182207 @default.
• W4220692731 creator A5009771930 @default.
• W4220692731 creator A5032646427 @default.
• W4220692731 creator A5033044041 @default.
• W4220692731 creator A5041477727 @default.
• W4220692731 creator A5048441665 @default.
• W4220692731 creator A5068690527 @default.
• W4220692731 creator A5079649403 @default.
• W4220692731 creator A5082560619 @default.
• W4220692731 creator A5082647122 @default.
• W4220692731 creator A5087872679 @default.
• W4220692731 date "2022-05-01" @default.
• W4220692731 modified "2023-10-18" @default.
• W4220692731 title "Inhibition of glutaminase 1-mediated glutaminolysis improves pathological cardiac remodeling" @default.
• W4220692731 cites W1553978925 @default.
• W4220692731 cites W1932780354 @default.
• W4220692731 cites W1996365670 @default.
• W4220692731 cites W2030867177 @default.
• W4220692731 cites W2070726059 @default.
• W4220692731 cites W2085557310 @default.
• W4220692731 cites W2086619682 @default.
• W4220692731 cites W2086828019 @default.
• W4220692731 cites W2092152920 @default.
• W4220692731 cites W2105770144 @default.
• W4220692731 cites W2132117833 @default.
• W4220692731 cites W2148134248 @default.
• W4220692731 cites W2150171020 @default.
• W4220692731 cites W2150738902 @default.
• W4220692731 cites W2153819921 @default.
• W4220692731 cites W2155018999 @default.
• W4220692731 cites W2158676604 @default.
• W4220692731 cites W2169058037 @default.
• W4220692731 cites W2188527725 @default.
• W4220692731 cites W2274126817 @default.
• W4220692731 cites W2317552858 @default.
• W4220692731 cites W2403029062 @default.
• W4220692731 cites W2427094903 @default.
• W4220692731 cites W2503851771 @default.
• W4220692731 cites W2510865896 @default.
• W4220692731 cites W2587537033 @default.
• W4220692731 cites W2769242667 @default.
• W4220692731 cites W2781725704 @default.
• W4220692731 cites W2809295497 @default.
• W4220692731 cites W2925036255 @default.
• W4220692731 cites W2985380082 @default.
• W4220692731 cites W2990255056 @default.
• W4220692731 cites W2997007028 @default.
• W4220692731 cites W3003299879 @default.
• W4220692731 cites W3040960259 @default.
• W4220692731 cites W3083797014 @default.
• W4220692731 cites W3096532134 @default.
• W4220692731 cites W3099019722 @default.
• W4220692731 cites W3118735616 @default.
• W4220692731 cites W3120626955 @default.
• W4220692731 cites W3165091443 @default.
• W4220692731 cites W4206498374 @default.
• W4220692731 doi "https://doi.org/10.1152/ajpheart.00692.2021" @default.
• W4220692731 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35275762" @default.
• W4220692731 hasPublicationYear "2022" @default.
• W4220692731 type Work @default.
• W4220692731 citedByCount "3" @default.
• W4220692731 countsByYear W42206927312022 @default.
• W4220692731 countsByYear W42206927312023 @default.
• W4220692731 crossrefType "journal-article" @default.
• W4220692731 hasAuthorship W4220692731A5000182207 @default.
• W4220692731 hasAuthorship W4220692731A5009771930 @default.
• W4220692731 hasAuthorship W4220692731A5032646427 @default.
• W4220692731 hasAuthorship W4220692731A5033044041 @default.
• W4220692731 hasAuthorship W4220692731A5041477727 @default.
• W4220692731 hasAuthorship W4220692731A5048441665 @default.
• W4220692731 hasAuthorship W4220692731A5068690527 @default.
• W4220692731 hasAuthorship W4220692731A5079649403 @default.
• W4220692731 hasAuthorship W4220692731A5082560619 @default.
• W4220692731 hasAuthorship W4220692731A5082647122 @default.
• W4220692731 hasAuthorship W4220692731A5087872679 @default.
• W4220692731 hasConcept C109549099 @default.
• W4220692731 hasConcept C11960822 @default.
• W4220692731 hasConcept C126322002 @default.
• W4220692731 hasConcept C134018914 @default.
• W4220692731 hasConcept C17137333 @default.
• W4220692731 hasConcept C185592680 @default.
• W4220692731 hasConcept C2777420927 @default.
• W4220692731 hasConcept C2778160063 @default.
• W4220692731 hasConcept C2779349466 @default.
• W4220692731 hasConcept C2780559512 @default.
• W4220692731 hasConcept C515207424 @default.
• W4220692731 hasConcept C55493867 @default.
• W4220692731 hasConcept C71924100 @default.
• W4220692731 hasConcept C86803240 @default.
• W4220692731 hasConcept C95444343 @default.
• W4220692731 hasConceptScore W4220692731C109549099 @default.
• W4220692731 hasConceptScore W4220692731C11960822 @default.
• W4220692731 hasConceptScore W4220692731C126322002 @default.
• W4220692731 hasConceptScore W4220692731C134018914 @default.
• W4220692731 hasConceptScore W4220692731C17137333 @default.
• W4220692731 hasConceptScore W4220692731C185592680 @default.

• next